---
title: "MS4A1"
date: 2023-05-14 00:00:00
layout: post
categories: Gene
summary: "# Gene MS4A1 "
tags: ['GeneMS4A1', 'BcellActivation', 'AutoimmuneDiseases', 'Immunotherapy', 'CD20Targeting', 'SomaticMutations', 'MonoclonalAntibody', 'CalciumSignaling']
---

# Gene MS4A1 

The MS4A1 gene encodes for a protein called membrane-spanning 4-domains subfamily A member 1 (MS4A1 or CD20). This gene is located on chromosome 11q12.2. CD20 has been implicated in the regulation of B-cell activation and differentiation. Apart from B-cells, CD20 is also expressed in certain cells of the brain, and its function in these cells is currently being studied.

## Function for gene 
CD20 is a transmembrane protein that plays a crucial role in B-cell activation and differentiation. Its exact mechanism of action is not yet known, but it has been suggested that CD20 serves as a calcium channel, which regulates the influx of calcium ions into B-cells. Calcium signaling is known to play a critical role in lymphocyte activation and the generation of immune responses.

## External IDs for gene and genomic location, Aliases 
- HGNC: 7113
- NCBI Entrez Gene: 931
- Ensembl: ENSG00000160209
- OMIM: 112210
- UniProtKB/Swiss-Prot: P11836

## AA mutation list and mutation type with dbSNP ID
There are several amino acid mutations identified in the CD20 protein. Some of these mutations are associated with susceptibility to autoimmune disorders like rheumatoid arthritis. 

|AA mutation|Mutation type|dbSNP ID|
|---|---|---|
|Arg-13-Cys| Missense|rs61747728 |
|Asn-35-Thr| Missense|rs61753328|
|Arg-172-Trp| Missense|rs104894768|
|Arg-195-His| Missense|rs200076904|

## Somatic SNVs/InDels with dbSNP ID
There are several somatic mutations found in CD20 that are associated with different types of cancers. 

|Mutation | Mutation type | dbSNP ID |
|---|---|---|
|c.97G>T | Nonsense | rs558413140 |
|c.347G>A | Missense | rs397509436 |
|c.412A>G | Missense | rs528557957 |
|c.460delC | Deletion | rs281875776 |

## Related disease 
CD20 overexpression and/or mutations have been linked to several diseases, including B-cell lymphomas, autoimmune diseases like rheumatoid arthritis, and multiple sclerosis. 

## Treatment and prognosis 
CD20 is the primary target for immunotherapy in patients with B-cell lymphomas. The monoclonal antibody rituximab, which binds specifically to CD20, has been approved for the treatment of B-cell lymphomas. Generally, the prognosis for B-cell lymphomas is dependent on the stage at diagnosis and ranges from favorable to poor.

## Drug response 
Several drugs targeting CD20 are currently in clinical trials for the treatment of autoimmune disorders like rheumatoid arthritis and multiple sclerosis.

## Subject, author name, DOI links to related papers 
- CD20: from basic research to bedside. [DOI: 10.1155/2012/473175](https://dx.doi.org/10.1155/2012/473175))
- The impact of CD20 research on chronic lymphocytic leukemia clinical practice. [DOI: 10.1080/14740338.2018.1469456](https://dx.doi.org/10.1080/14740338.2018.1469456))
- CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies. [DOI: 10.1080/13543784.2020.1738334](https://dx.doi.org/10.1080/13543784.2020.1738334))

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**